**Question:** Vasopressor of choice in hypotension produced during subarachnoid hemorrhage (SAH)

**Core Concept:**
Subarachnoid hemorrhage is a medical emergency caused by bleeding into the subarachnoid space, typically due to a ruptured aneurysm. Hypotension is a common complication in patients with subarachnoid hemorrhage, leading to decreased perfusion pressure and possible organ dysfunction. Vasopressors are medications used to increase blood pressure in situations where hypotension is a concern.

**Why the Correct Answer is Right:**
In the context of hypotension following subarachnoid hemorrhage, the vasopressor of choice is norepinephrine (Noradrenaline). Norepinephrine is a potent vasopressor that acts on alpha-adrenergic receptors and has some effect on beta-adrenergic receptors. It increases systemic vascular resistance (SVR) and cardiac output (CO), ultimately leading to improved blood pressure and perfusion pressure in patients with subarachnoid hemorrhage.

**Why Each Wrong Option is Incorrect:**

A. Epinephrine (Adrenaline): While epinephrine is also a potent vasopressor acting on beta-adrenergic receptors, its use in this context is less effective due to its weak action on alpha-adrenergic receptors. Additionally, its short half-life requires frequent administration, which can lead to fluctuations in blood pressure.

B. Phenylephrine: Phenylephrine is a selective alpha-1 adrenergic receptor agonist, which can lead to worsening of cerebral perfusion pressure due to reduced cerebral blood flow. Its use is contraindicated in subarachnoid hemorrhage.

C. Dopamine: Dopamine is a mixed dopaminergic agonist, acting on both alpha and beta receptors. However, its clinical effects are relatively weak, and its use may not provide sufficient vasoconstriction to counteract the effects of subarachnoid hemorrhage.

D. Vasopressin: Vasopressin, also known as antidiuretic hormone (ADH), is a potent vasopressor acting on V1 receptors. However, its use in this context is controversial due to its potential to worsen cerebral perfusion pressure by reducing cerebral blood flow. Additionally, it may not provide sufficient vasoconstriction to counteract the effects of subarachnoid hemorrhage.

**Clinical Pearls:**

1. In patients with subarachnoid hemorrhage, the goal of vasopressor therapy is to maintain adequate cerebral perfusion pressure while minimizing the risk of worsening cerebral blood flow.
2. The choice of vasopressor should be tailored to the specific receptor subtype involved in the pathophysiology of subarachnoid hemorrhage.
3. Frequent monitoring of blood pressure and cerebral perfusion pressure is essential when using vasopressors in subarachnoid hemorrhage patients to ensure optimal treatment outcomes.
4. In cases of refractory hypotension, consider using vasopressin (ADH), but be aware of its potential to worsen cerebral blood flow.